{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:09:57Z","timestamp":1792602597548,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semnuclmed.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T08:28:36Z","timestamp":1665563316000},"page":"389-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Modern PET-Guided Radiotherapy Planning and Treatment for Malignant Lymphoma"],"prefix":"10.1053","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-4203","authenticated-orcid":false,"given":"Niklas Benedikt","family":"Pepper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-7013","authenticated-orcid":false,"given":"Michael","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0001","unstructured":"Zelenetz A, Gordon LI, Abramson JS, et al. NCCN clinical practice guidelines in oncology: B-cell lymphomas, version 3.2022 NCCN Guidelines 2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed June 1, 2022."},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0002","unstructured":"Hoppe RT, Advani R, Ai WZ, et al. NCCN clinical practice guidelines in oncology: Hodgkin lymphoma, version 2.2022 NCCN Guidelines 2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf. Accessed June 1, 2022."},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0003","unstructured":"Horwitz SM, Ansell S, Ai WZ, et al. NCCN clinical practice guidelines in oncology: T-cell lymphoma, version 2.2022 NCCN Guidelines 2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf. Accessed June 1, 2022."},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0004","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0007","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0008","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0009","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0010","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten, Kurzversion 3.1, 2022; AWMF Registernummer: 018\/029 OL. Available at: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/hodgkin-lymphom. Accessed June 25, 2022."},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0011","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJM196804182781606","article-title":"Clinical Evaluation and Radiotherapeutic Management of Hodgkin's Disease and the Malignant Lymphomas","volume":"278","author":"Kaplan","year":"1968","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0012","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe,AWMF): Diagnostik, Therapie und Nachsorge f\u00fcr erwachsene Patient*innen mit einem diffusen gro\u00dfzelligen B-Zell-Lymphom und verwandten Entit\u00e4ten, Langversion 1.01, Juni 2022, AWMF-Registernummer: 018\/038OL. Available at: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/dlbcl. Accessed June 25, 2022."},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0013","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0014","first-page":"2562","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group [published correction appears","volume":"34","author":"Barrington","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijrobp.2014.02.006","article-title":"A prospective study of \u00b9\u2078FDG-PET with CT co-registration for radiation treatment planning of lymphomas and other hematologic malignancies","volume":"89","author":"Terezakis","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0016","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/biomedicines9050561","article-title":"Radiotherapy in Follicular Lymphoma Staged by 18F-FDG-PET\/CT: A German Monocenter Study","volume":"9","author":"Karsten","year":"2021","journal-title":"Biomedicines"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjh.12601","article-title":"When should FDG-PET be used in the modern management of lymphoma?","volume":"164","author":"Barrington","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/10428194.2014.919635","article-title":"Comparison of positron emission tomography\/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma","volume":"56","author":"Bednaruk-M\u0142y\u0144ski","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0019","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1148\/radiol.2018181519","article-title":"Effect of PET\/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry","volume":"290","author":"Metser","year":"2019","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4137\/CMBD.S38468","article-title":"Low-Dose PET\/CT and Full-Dose Contrast-Enhanced CT at the Initial Staging of Localized Diffuse Large B-Cell Lymphomas","volume":"9","author":"Sabat\u00e9-Llobera","year":"2016","journal-title":"Clin Med Insights Blood Disord"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0021","first-page":"331","volume":"134","author":"Brady","year":"2019"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0022","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.semnuclmed.2022.09.001_bib0023","article-title":"Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL","volume":"35","author":"Pfreundschuh","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0024","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0026","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavorable Hodgkin lymphoma (GHSG HD17): a multicenter, open-label, randomized, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0027","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2006.00802.x","article-title":"Clinical impact of FDG-PET\/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma","volume":"78","author":"Hutchings","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0028","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.2013.53.2507","article-title":"Assessment of tumor size reduction improves outcome prediction of positron emission tomography\/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma","volume":"32","author":"Kobe","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0029","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2014.04.026","article-title":"Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients","volume":"89","author":"Girinsky","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijrobp.2010.06.044","article-title":"[\u00b9\u2078F]FDG-positron emission tomography co-registration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies","volume":"81","author":"Terezakis","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0031","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ijrobp.2009.11.048","article-title":"Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study","volume":"79","author":"Pommier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0032","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2010.02.024","article-title":"Co-registration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition","volume":"80","author":"Metwally","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/a-1666-2572","article-title":"18F-FDG PET-CT in Radiotherapy of localized Follicular Lymphoma","volume":"45","author":"Rehn","year":"2022","journal-title":"Angewandte Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jicru_ndq002","article-title":"Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT)","volume":"10","author":"DeLuca","year":"2010","journal-title":"Journal of the ICRU"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.semnuclmed.2017.09.006","article-title":"PET\/CT in Radiation Therapy Planning","volume":"48","author":"Specht","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0037","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0038","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2015.02.008","article-title":"Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma","volume":"92","author":"Hoppe","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0039","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3413\/Nukmed-0746-15-06","article-title":"Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma","volume":"54","author":"Kobe","year":"2015","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2019.02.001","article-title":"The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"104","author":"Mikhaeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0041","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3109\/10428194.2013.784967","article-title":"Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma","volume":"54","author":"Dabaja","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0042","unstructured":"Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT)"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0043","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00066-020-01705-w","article-title":"Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic: Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance","volume":"196","author":"Oertel","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0044","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0045","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial","volume":"22","author":"van Heek","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1053\/j.semnuclmed.2022.09.001_bib0046","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2967\/jnumed.118.210047","article-title":"Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma","volume":"60","author":"Mettler","year":"2018","journal-title":"Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0047","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0048","article-title":"Radiomics signature from [18F]FDG PET images for prognosis predication of primary gastrointestinal diffuse large B cell lymphoma [published online ahead of print, 2022 Mar 17]","author":"Jiang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0049","article-title":"Prognostic Value of Radiomic Features of 18F-FDG PET\/CT in Patients With B-Cell Lymphoma Treated With CD19\/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0050","article-title":"Distinction of lymphoma from sarcoidosis at FDG PET\/CT - evaluation of radiomic-feature guided machine learning versus human reader performance [published online ahead of print, 2022 May 19]","volume":"121","author":"Lovinfosse","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0051","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/cancers14071711","article-title":"Discovery of Pre-Treatment FDG PET\/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma","volume":"14","author":"Frood","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0052","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00066-019-01541-7","article-title":"De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma. Deeskalierte Strahlentherapie beim indolenten prim\u00e4r kutanen B-Zell-Lymphom","volume":"196","author":"Oertel","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0053","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.21873\/anticanres.14400","article-title":"Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma","volume":"40","author":"Rehn","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0054","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0055","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study","volume":"2","author":"Herfarth","year":"2018","journal-title":"Hemasphere"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0056","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s13063-019-3614-y","volume":"20","author":"K\u00f6nig","year":"2019","journal-title":"Trials"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0057","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0058","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-020-05098-x","article-title":"FDG PET\/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma","volume":"48","author":"L\u00f8ndalen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0059","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/1078-0432.CCR-20-3303","article-title":"Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial","volume":"27","author":"Voltin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0060","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.3390\/ijms21124309","article-title":"Current Perspectives on 89Zr-PET Imaging","volume":"21","author":"Yoon","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169828","article-title":"Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma","volume":"12","author":"Jauw","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0062","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.ijrobp.2007.04.035","volume":"69","author":"Eich","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0063","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00066-005-1437-0","article-title":"The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel","volume":"181","author":"M\u00fcller","year":"2005","journal-title":"Strahlenther Onkol"},{"key":"10.1053\/j.semnuclmed.2022.09.001_bib0064","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/01.coc.0000092701.47861.81","article-title":"The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imaging","volume":"27","author":"Eich","year":"2004","journal-title":"Am J Clin Oncol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:40:35Z","timestamp":1757544035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0001299822000861"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.09.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern PET-Guided Radiotherapy Planning and Treatment for Malignant Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}